[go: up one dir, main page]

TR200200843T2 - İşemi'nin Tedavisi için olan bileşikler - Google Patents

İşemi'nin Tedavisi için olan bileşikler

Info

Publication number
TR200200843T2
TR200200843T2 TR2002/00843T TR200200843T TR200200843T2 TR 200200843 T2 TR200200843 T2 TR 200200843T2 TR 2002/00843 T TR2002/00843 T TR 2002/00843T TR 200200843 T TR200200843 T TR 200200843T TR 200200843 T2 TR200200843 T2 TR 200200843T2
Authority
TR
Turkey
Prior art keywords
isemia
compounds
treatment
agonists
hypoxia
Prior art date
Application number
TR2002/00843T
Other languages
English (en)
Inventor
Masamune Hiroko
Paul Deninno Michael
William Scott Robert
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of TR200200843T2 publication Critical patent/TR200200843T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

A3 agonistleri, bu A3 agonistlerinin ve bu A3 agonistlerini içeren farmasötik bilesimlerin kullanim yöntemleri A3 agonistleri isemi ya da hipoksiya'dan kaynaklanan doku hasarinin azaltilmasi için yararlidirlar.
TR2002/00843T 1999-09-30 2000-09-22 İşemi'nin Tedavisi için olan bileşikler TR200200843T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15682899P 1999-09-30 1999-09-30

Publications (1)

Publication Number Publication Date
TR200200843T2 true TR200200843T2 (tr) 2002-07-22

Family

ID=22561263

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00843T TR200200843T2 (tr) 1999-09-30 2000-09-22 İşemi'nin Tedavisi için olan bileşikler

Country Status (41)

Country Link
EP (1) EP1216257B1 (tr)
JP (1) JP2003510331A (tr)
KR (1) KR100481605B1 (tr)
CN (1) CN1374967A (tr)
AP (1) AP2002002458A0 (tr)
AR (1) AR029887A1 (tr)
AT (1) ATE312117T1 (tr)
AU (1) AU778185B2 (tr)
BG (1) BG106636A (tr)
BR (1) BR0014384A (tr)
CA (1) CA2386079A1 (tr)
CO (1) CO5180581A1 (tr)
CR (1) CR6592A (tr)
CZ (1) CZ20021020A3 (tr)
DE (1) DE60024649D1 (tr)
EA (1) EA005422B1 (tr)
EC (1) ECSP003682A (tr)
EE (1) EE200200172A (tr)
GE (1) GEP20043241B (tr)
GT (1) GT200000161A (tr)
HK (1) HK1049011A1 (tr)
HR (1) HRP20020253A2 (tr)
HU (1) HUP0202807A3 (tr)
IL (1) IL148222A0 (tr)
IS (1) IS6286A (tr)
MA (1) MA26822A1 (tr)
MX (1) MXPA02003308A (tr)
MY (1) MY133996A (tr)
NO (1) NO20021474L (tr)
NZ (1) NZ517177A (tr)
OA (1) OA12021A (tr)
PA (1) PA8503301A1 (tr)
PE (1) PE20010696A1 (tr)
PL (1) PL357371A1 (tr)
SK (1) SK4182002A3 (tr)
TN (1) TNSN00191A1 (tr)
TR (1) TR200200843T2 (tr)
UA (1) UA73525C2 (tr)
WO (1) WO2001023399A1 (tr)
YU (1) YU23102A (tr)
ZA (1) ZA200202461B (tr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
EP1241176A1 (en) * 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
HUP0401853A2 (hu) * 2001-11-02 2004-12-28 Aventis Pharmaceuticals Inc. Gyógyászati készítmény, ami egy adenozin A1/A2 agonistát és nátrium-hidrogén csere inhibitort tartalmaz
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
AU2003235466C1 (en) * 2002-04-18 2008-03-20 Gilead Palo Alto, Inc. Method for treating arrhythmias
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
CA2543913A1 (en) * 2003-11-10 2005-05-26 Schering Aktiengesellschaft Benzylether amine compounds useful as ccr-5 antagonists
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
KR20070085093A (ko) 2004-03-24 2007-08-27 파스젠, 엘엘씨. Ａｍｐ-활성화 단백질 키나아제의 약리학적 저해에 의한신규한 신경 보호 방법
NZ551077A (en) 2004-05-07 2009-05-31 Janssen Pharmaceutica Nv Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
JP4642847B2 (ja) * 2004-07-28 2011-03-02 キャン−ファイト・バイオファーマ・リミテッド シェーグレン症候群を含むドライアイ疾患治療用アデノシンａ３レセプターアゴニスト
CA2576255A1 (en) * 2004-08-09 2006-02-16 Universite Catholique De Louvain Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases
JP5208505B2 (ja) * 2004-08-30 2013-06-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ １１−ベータヒドロキシステロイドデヒドロゲナーゼ阻害剤としてのｎ−２アダマンタニル−２−フェノキシ−アセトアミド誘導体
WO2006024628A1 (en) 2004-08-30 2006-03-09 Janssen Pharmaceutica N.V. Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
MX2009003185A (es) 2006-09-29 2009-04-03 Novartis Ag Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
AU2007315234A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
CN101910153B (zh) 2008-01-11 2014-01-22 诺华股份有限公司 作为激酶抑制剂的嘧啶类
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
EP2456419B1 (en) 2009-07-21 2016-11-23 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
PE20121148A1 (es) 2009-08-17 2012-09-07 Intellikine Llc Compuestos heterociclicos y usos de los mismos
BR112012008061A2 (pt) 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
BR112014027983B1 (pt) 2012-05-08 2022-05-24 Aeromics, Inc Uso de inibidores de aquaporina seletivos
RU2559776C2 (ru) * 2012-08-20 2015-08-10 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции для лечения цереброваскулярных расстройств и способы их изготовления
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
RU2691951C2 (ru) 2013-11-06 2019-06-19 Аэромикс, Инк. Новые составы
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
RU2611339C2 (ru) * 2014-02-17 2017-02-21 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции с пролонгированным высвобождением для лечения цереброваскулярных расстройств
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
AU2015294889B2 (en) 2014-07-31 2018-03-15 Novartis Ag Combination therapy
RU2582961C1 (ru) * 2015-03-04 2016-04-27 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Фармацевтические композиции в жидких лекарственных формах для лечения цереброваскулярных расстройств и способы их изготовления
US12324807B2 (en) 2018-06-01 2025-06-10 Cornell University Combination therapy for PI3K-associated disease or disorder
RU2712150C1 (ru) * 2019-08-22 2020-01-24 Общество с ограниченной ответственностью "ЦЕНТР ТРАНСФЕРА БИОТЕХНОЛОГИЙ ОКА-Биотех" ПРИМЕНЕНИЕ ТЕТРААЦЕТИЛИРОВАННОГО 5-АМИНО-4-КАРБАМОИЛИМИДАЗОЛИЛ-1-β-D-РИБОФУРАНОЗИДА В КАЧЕСТВЕ ИНГИБИТОРА ПРОТЕИНКИНАЗЫ Cδ
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK62692D0 (tr) * 1992-05-14 1992-05-14 Novo Nordisk As
TW336938B (en) * 1992-05-21 1998-07-21 Pfizer Calcium channel blocking polypeptides from filistata hibernalis
US5773423A (en) * 1993-07-13 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists

Also Published As

Publication number Publication date
HRP20020253A2 (en) 2004-04-30
HUP0202807A2 (hu) 2002-12-28
EA200200316A1 (ru) 2002-08-29
AU778185B2 (en) 2004-11-18
MA26822A1 (fr) 2004-12-20
PE20010696A1 (es) 2001-07-05
CZ20021020A3 (cs) 2003-04-16
WO2001023399A1 (en) 2001-04-05
BR0014384A (pt) 2002-07-02
EP1216257A1 (en) 2002-06-26
ATE312117T1 (de) 2005-12-15
EP1216257B1 (en) 2005-12-07
YU23102A (sh) 2006-01-16
JP2003510331A (ja) 2003-03-18
HK1049011A1 (zh) 2003-04-25
UA73525C2 (en) 2005-08-15
ZA200202461B (en) 2003-05-28
HUP0202807A3 (en) 2005-02-28
NO20021474D0 (no) 2002-03-25
CA2386079A1 (en) 2001-04-05
PL357371A1 (en) 2004-07-26
AU7035200A (en) 2001-04-30
MY133996A (en) 2007-11-30
DE60024649D1 (de) 2006-01-12
CR6592A (es) 2004-02-23
EE200200172A (et) 2003-06-16
ECSP003682A (es) 2002-04-23
MXPA02003308A (es) 2002-10-04
IL148222A0 (en) 2002-09-12
GT200000161A (es) 2002-03-22
NZ517177A (en) 2003-10-31
PA8503301A1 (es) 2003-06-30
NO20021474L (no) 2002-05-22
CN1374967A (zh) 2002-10-16
KR100481605B1 (ko) 2005-04-08
AP2002002458A0 (en) 2002-06-30
CO5180581A1 (es) 2002-07-30
AR029887A1 (es) 2003-07-23
EA005422B1 (ru) 2005-02-24
OA12021A (en) 2006-04-19
GEP20043241B (en) 2004-05-25
SK4182002A3 (en) 2003-04-01
KR20020034206A (ko) 2002-05-08
TNSN00191A1 (fr) 2005-11-10
BG106636A (bg) 2003-01-31
IS6286A (is) 2002-02-26

Similar Documents

Publication Publication Date Title
TR200200843T2 (tr) İşemi'nin Tedavisi için olan bileşikler
TR200002480T2 (tr) İzaşemi tedavisi için guanidin türevleri
BR0200782A (pt) Compostos para o tratamento da isquemia
DK1140993T3 (da) Glycopeptidderivater og farmaceutiske præparater indeholdende dem
PT1200412E (pt) Agentes anti-proliferativos de imidazole
TR200101793T2 (tr) CCR5 modülatörleri olarak azabisikloalkanlar
TR199802136T2 (tr) IMPDH enzimi inhibitörleri olarak üre türevleri.
TR200103186T2 (tr) MEK enzimlerinin inhibitörleri olarak kinolin türevleri
DK1093819T3 (da) Forbindelse og præparat til tilförsel af aktive midler
BR9811099A (pt) Inibidores de urocinase
ATE300541T1 (de) Pyrazolopyridinderivate
DE69904804D1 (de) Glucocorticoid selektive entzündungshemmende mittel
EE200200208A (et) Oligosahhariidid, nende valmistamismeetod ja kasutamine ning farmatseutilised kompositsioonid
TR200101663T2 (tr) Pro-kollajen c-proteinaz inhibitörleri
TR200102524T2 (tr) Dihetero sübstitüe edilmiş metaloproteaz inhibitörleri.
ATE253359T1 (de) Antithrombotische mittel
NO983444D0 (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
ID25478A (id) Agonis 5-ht1f
SE9904128D0 (sv) Novel compounds
ATE286395T1 (de) Antithrombotische mittel
PT1244643E (pt) Inibidores da triptase
PT1244614E (pt) Inibidores de triptase
ATE250076T1 (de) 6-o-carbamat ketolide derivate
DE60039122D1 (de) 6-o-alkyl-2-nor-2-substituierte ketolidderivate
DE60014915D1 (de) Hypoxanthin- und thiohypxanthin-verbindungen